Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Getting Started With Addiction Care: Screening and Evaluation (16 mins)

Source: Navigating the Nexus of Addiction, HCV Infection, and HIV Infection
Review the essentials of opioid use disorder screening, diagnosis, and patient engagement in assessing readiness for treatment, with a strong emphasis on the role of harm reduction throughout this process.
Sandra Springer, MD
Program Director
Christian Ramers Headshot
Christian B. Ramers, MD, MPH
Released: February 6, 2020 Expiration: No longer available for credit

This program is divided into several short segments which you can step through using the Video Chapters widget.

Related Content

Breve vlog de la Dra. Alicia Piñeirúa Menéndez sobre la optimización del TAR en un paciente con VIH y tuberculosis activa en México de Clinical Care Options (CCO)

person default Alicia Piñeirúa Menéndez, MD, MPH Released: May 20, 2022

Preguntas respondidas por expertas de Clinical Care Options (CCO) sobre las mejores prácticas para cambiar el TAR en pacientes suprimidos en México.

person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Released: May 17, 2022
Introductory Case
Question and Answer Session

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN Jasjit Gill, BSPharm, PharmD Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 10, 2022 Expired: May 9, 2023

Expert selections of data for state-of-the-art switch strategies in virologically suppressed patients.

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Paul E. Sax, MD Released: May 6, 2022

Video Chapters

Intersection of OUD and ID
Benefits of Integrated Care
OUD Screening and Evaluation
Medication for OUD
Additional Considerations
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
American Society of Addiction Medicine
Educational grant provided by:
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings